G1 Therapeutics: trilaciclib shows benefits for lung cancer patients

By Jenni Spinner

- Last updated on GMT

(Image: Getty/mr suphachai praserdumrongchai)
(Image: Getty/mr suphachai praserdumrongchai)

Related tags Lung cancer Clinical trials Oncology Research and development

The company will present data from recent Phase 2 trials of the investigational drug at the upcoming ASCO20 virtual conference on May 29.

G1 Therapeutics, a clinical-stage oncology firm, announced the upcoming presentation of data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational drug trilaclib. The company will unveil the data May 29 at the ASCO20 (American Society of Clinical Oncology) Virtual Scientific Program.

According to the company, trilaciclib administered to patients prior to chemotherapy showed significantly reduced rates of myelosuppression and the need for related supportive care interventions compared with patients receiving chemotherapy treatment alone.

Raj Malik, chief medical officer and senior vice president of R&D for the company, said the data indicates trilaciclib shows promise to improve outcomes for chemotherapy patients.

Patients with chemotherapy-induced myelosuppression are especially vulnerable and often require multiple rescue interventions that are burdensome to both the patient and the healthcare system​,” he said. “Trilaciclib has the potential to be the first proactively administered myelopreservation therapy that can make chemotherapy safer and improve the patient experience.​”

Myelosuppression is the result of damage to bone marrow cells, and is one of the most common side effects of chemotherapy. The condition often calls for rescue interventions (like growth factors and blood or platelet transfusions) and can lead to chemotherapy dose delays and reductions.

Additionally, resulting immune cell damage may decrease the ability of the immune system to fight the cancer, or infections. Trilaciclib is an investigational therapy intended to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes.

G1 Therapeutics reports it intends to complete an NDA submission for trilaciclib for myelopreservation in small-cell lung cancer in the second quarter of the year. The drug has been assigned Breakthrough Therapy Designation by the US Food and Drug Administration (FDA).

The abstracts G1 Therapeutics will be presenting during the ASCO20 event are:

  • “Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer”
  • “Real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey of patients with cancer”
  • “Title: Real-world burden of myelosuppression in patients with small cell lung cancer: retrospective, longitudinal data analysis”

Additional details are available at the event website, meetings.asco.org/am/virtual-format

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us